MCK McKesson Corporation

Investing.com -- McKesson Corporation (NYSE:MCK) shares rose 4.4% Thursday following the announcement of an extended pharmaceutical distribution agreement with CVS Health through June 2032.

Here, we highlight five medical supplies stocks, MCK, CAH, BDX, MMSI and PDEX, with strong potential that investors should keep on their watchlist amid improving industry prospects.

McKesson (MCK) reached $853.81 at the closing of the latest trading day, reflecting a -1.27% change compared to its last close.

McKesson's specialty distribution, oncology and GLP-1 growth are driving earnings, while drug pricing, margin pressure and policy uncertainty pose challenges.

AbbVie bets on pipeline diversification amid patent cliffs, while J&J's higher profitability masks litigation risks, a choice between growth ambition and defensive stability.

AbbVie pivots toward newer immunology drugs while Pfizer leans on acquisitions to offset pandemic decline, but their financial profiles and valuations tell starkly different stories.

McKesson (MCK) is back in focus after its share price dipped 1.2%, trailing the broader market, as investors weigh mixed earnings estimates against the company’s raised full-year adjusted EPS guidance and specialty-led healthcare footprint. Recent trading has been choppy for McKesson, with the share price slipping 3.95% over the past 30 days even after a 13.86% 90 day share price return and a 5.58% share price gain year to date. That near term hesitation sits against a much stronger backdrop,...

Novo Nordisk trades at a steep discount on earnings and sales, while AbbVie grapples with patent cliffs and pricing pressure, but profitability tells a different story.

AbbVie leans on legacy income and portfolio transition, while Eli Lilly rides explosive growth in weight-loss drugs, but at vastly different valuations.

CAH's specialty-led growth, stronger EPS outlook and improving estimate momentum set up a compelling case against MCK.

The latest trading day saw McKesson (MCK) settling at $880.5, representing a -1.2% change from its previous close.

Zacks.com users have recently been watching McKesson (MCK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

CAH is expanding its MSO strategy across specialty care, with Solaris and broader services aimed at scaling physician networks.

Since March 2026, McKesson has been in a holding pattern, floating around $872.99. The stock also fell short of the S&P 500’s 16.4% gain during that period.

AbbVie's immunology franchise is firing on all cylinders while Bristol Myers Squibb navigates revenue declines and legal uncertainty.

When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.

McKesson (MCK) closed at $887.29 in the latest trading session, marking a -1.36% move from the prior day.

Alluvium Asset Management, an asset management company, released its “Conventum – Alluvium Global Fund” second-quarter 2026 investor letter. The letter can be downloaded here. The second quarter reflected a sharp shift from geopolitical uncertainty and oil market volatility to a powerful equity rally led by semiconductor companies. Despite the broader market strength, the Fund declined […]

McKesson recently raised its full-year EPS guidance, projecting approximately 13%–15% growth (15%–17% excluding certain prior-year items), and outlined plans to rebrand its Medical-Surgical unit as Wellverse with a potential IPO targeted for the second half of 2027, alongside a pending acquisition of Precision Medicine Group to expand oncology and biopharma-services capabilities, subject to regulatory approval. This combination of upgraded earnings expectations, portfolio reshaping around...

AbbVie is profitable, growing, and paying a rising dividend. CRISPR is burning cash in pursuit of a gene-editing breakthrough that could reshape medicine.

McKesson (NYSE:MCK) executives said the company’s first-quarter performance supported a higher full-year earnings outlook, citing broad-based growth across its North American Pharmaceutical, Oncology & Multispecialty and Prescription Technology Solutions businesses. Speaking at the Morgan Stanl

Amgen trades at a cheaper valuation but carries higher leverage, while Vertex boasts pristine finances and 32% net margins, a classic trade-off between value and quality.

Cardinal Health's 29% rally reflects stronger specialty growth, MSO expansion and higher-margin assets, but cost pressures could test the uptrend.

Amgen is profitable and paying a growing dividend, while Revolution Medicines is burning cash to fund what could be one of the most important cancer drug launches in years.

One company is generating billions in revenue and raising its dividend. The other is burning cash in pursuit of a scientific breakthrough that could change how diseases are treated.

McKesson (MCK) closed at $880.86 in the latest trading session, marking a -1.21% move from the prior day.

AbbVie's diversified portfolio faces patent headwinds, while Novo Nordisk dominates a faster-growing market, but one trades at a steeper valuation.

Amgen trades at a fraction of Moderna's valuation, but one company is burning cash while the other generates billions, a critical divide for income-focused investors.

Cardinal (CAH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

McKesson (MCK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta year in and year out often become the legends of the investing world.

McKesson (NYSE:MCK) discussed its planned $2.25 billion acquisition of Precision Medicine Group, first-quarter operating trends and capital-allocation priorities during a presentation with Wells Fargo analyst Stephen Baxter. The company said Precision Medicine Group would expand two areas it has id

CVS Health is advancing Aetna's profitability turnaround, supported by stronger Health Care Benefits results, an improved MBR and operational initiatives.

Reuters reported that McKesson Corporation (NYSE:MCK) said it would buy privately held Precision Medicine Group in a deal valued at about $2.25 billion as part of a “years-long effort to strengthen its higher-growth businesses.” McKesson has been reshaping its portfolio by exiting non-core assets and streamlining its operations while investing in businesses such as oncology […]

AbbVie's immunology pivot is offsetting Humira's decline, while Pfizer trades at half the valuation despite patent risks ahead.

McKesson (MCK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

McKesson has outpaced the healthcare sector, and analysts remain highly optimistic about the stock’s outlook.

On the September 2 episode of Mad Money, Jim Cramer called Cardinal Health, Inc. (NYSE:CAH) one of his “absolute favorites” and mentioned its growing exposure to specialty pharmaceuticals and higher-margin healthcare services. Cardinal’s been running circles around McKesson and Cencora. They consistently put up the best numbers because this company has gradually become less of […]

Cencora raised its fiscal 2026 EPS outlook as specialty businesses fueled stronger profit growth despite mix, pricing and financing pressures.

Cardinal Health's generic volumes, profitable brand-to-generic conversions and Red Oak program continue to support Pharma profits.

The healthcare distributor said the incident affected a subset of customers in its oncology and medical-surgical businesses.

Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.

AbbVie trades cheaper but carries heavy revenue concentration; Johnson & Johnson boasts a fortress balance sheet and wider portfolio.

Amgen generated $8.1 billion in free cash flow in 2025, with a 21% net margin, while Axsome is scaling rapidly but still unprofitable.

McKesson Corporation (NYSE:MCK) has agreed to acquire privately held Precision Medicine Group for approximately $2.25 billion, as the healthcare company continues shifting its portfolio toward higher-growth businesses. Precision Medicine provides clinical research, laboratory testing, and commercialization services to biotechnology and pharmaceutical companies developing and launching new medicines. McKesson plans to integrate the company into its […]

McKesson (NYSE:MCK) announced an agreement to acquire Precision Medicine Group to expand its oncology and clinical research services. The deal is aimed at deepening McKesson's role in personalized medicine and specialty care, particularly in oncology and biopharma clinical trial support. The acquisition is expected to reshape McKesson's service mix across oncology practices, biopharma partners and clinical research organizations. For readers looking beyond McKesson to other potential...

MCK's $2.25B Precision Medicine Group deal aims to expand clinical research and commercialization services in oncology and multispecialty care.

A real-world study suggests Zepbound use could reduce the rates of hospital stays and ER visits. Elsewhere, McKesson sprung for a multibillion-dollar deal and J&J nabbed a noteworthy approval.

McKesson believes that the deal will support its clinical research and biopharmaceutical commercialisation services.

(Updates with market moves at the end of the day, and other changes, if any.) Stocks rose Tuesday